Movement Alert｜GENSCRIPT BIO Rises 6.17% in Regular Trading, CARVYKTI Sales Surge Nearly 50% YoY as Interim Results Review Approaches

Market Focus13:05

On August 7, GENSCRIPT BIO rose 6.17% in regular trading, trading at 21.14 HKD/share, with turnover of 788 million HKD, extending recent strong momentum.

On the news front, the company's associate Legend Biotech reported CARVYKTI Q2 trade sales of approximately USD 657 million, up 49.4% year-over-year and 10% quarter-over-quarter. First-half sales reached USD 1.254 billion, representing 55.1% year-over-year growth. Additionally, the company announced a board meeting scheduled for August 15 to review and approve interim results for the six months ended June 30 and consider interim dividend distribution.

The broader CXO sector also provided tailwinds, with WuXi AppTec reporting first-half non-GAAP net profit growth of approximately 89% year-over-year, lifting sector-wide sentiment. Within the Life Sciences Tools and Services sector, WUXI XDC gained 9.39%, PHARMARON rose 8.89%, WUXI BIO added 6.57%, INSILICO climbed 6.25%, and WUXI APPTEC advanced 5.29%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122967292?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 13:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122967292","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 6.17% in Regular Trading, CARVYKTI Sales Surge Nearly 50% YoY as Interim Results Review Approaches","media":"Market Focus","content":"<p><p>On August 7, GENSCRIPT BIO rose 6.17% in regular trading, trading at 21.14 HKD/share, with turnover of 788 million HKD, extending recent strong momentum.</p><p>On the news front, the company's associate Legend Biotech reported CARVYKTI Q2 trade sales of approximately USD 657 million, up 49.4% year-over-year and 10% quarter-over-quarter. First-half sales reached USD 1.254 billion, representing 55.1% year-over-year growth. Additionally, the company announced a board meeting scheduled for August 15 to review and approve interim results for the six months ended June 30 and consider interim dividend distribution.</p><p>The broader CXO sector also provided tailwinds, with WuXi AppTec reporting first-half non-GAAP net profit growth of approximately 89% year-over-year, lifting sector-wide sentiment. Within the Life Sciences Tools and Services sector, WUXI XDC gained 9.39%, PHARMARON rose 8.89%, WUXI BIO added 6.57%, INSILICO climbed 6.25%, and WUXI APPTEC advanced 5.29%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 6.17% in Regular Trading, CARVYKTI Sales Surge Nearly 50% YoY as Interim Results Review Approaches</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 6.17% in Regular Trading, CARVYKTI Sales Surge Nearly 50% YoY as Interim Results Review Approaches\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 13:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, GENSCRIPT BIO rose 6.17% in regular trading, trading at 21.14 HKD/share, with turnover of 788 million HKD, extending recent strong momentum.</p><p>On the news front, the company's associate Legend Biotech reported CARVYKTI Q2 trade sales of approximately USD 657 million, up 49.4% year-over-year and 10% quarter-over-quarter. First-half sales reached USD 1.254 billion, representing 55.1% year-over-year growth. Additionally, the company announced a board meeting scheduled for August 15 to review and approve interim results for the six months ended June 30 and consider interim dividend distribution.</p><p>The broader CXO sector also provided tailwinds, with WuXi AppTec reporting first-half non-GAAP net profit growth of approximately 89% year-over-year, lifting sector-wide sentiment. Within the Life Sciences Tools and Services sector, WUXI XDC gained 9.39%, PHARMARON rose 8.89%, WUXI BIO added 6.57%, INSILICO climbed 6.25%, and WUXI APPTEC advanced 5.29%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1122967292","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122967292","pubTimestamp":1786079159,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, GENSCRIPT BIO rose 6.17% in regular trading, trading at 21.14 HKD/share, with turnover of 788 million HKD, extending recent strong momentum.On the news front, the company's associate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|随着中期业绩审查临近，金斯瑞生物常规交易上涨 6.17%，CARVYKTI 销售额同比飙升近 50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 7, GENSCRIPT BIO rose 6.17% in regular trading, trading at 21.14 HKD/share, with turnover of 788 million HKD, extending recent strong momentum.On the news front, the company's associate Legend Biotech reported CARVYKTI Q2 trade sales of approximately USD 657 million, up 49.4% year-over-year and 10% quarter-over-quarter. First-half sales reached USD 1.254 billion, representing 55.1% year-over-year growth. Additionally, the company announced a board meeting scheduled for August 15 to review and approve interim results for the six months ended June 30 and consider interim dividend distribution.The broader CXO sector also provided tailwinds, with WuXi AppTec reporting first-half non-GAAP net profit growth of approximately 89% year-over-year, lifting sector-wide sentiment. Within the Life Sciences Tools and Services sector, WUXI XDC gained 9.39%, PHARMARON rose 8.89%, WUXI BIO added 6.57%, INSILICO climbed 6.25%, and WUXI APPTEC advanced 5.29%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122967292","isCrawlerRequest":true}